KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Ionis Pharmaceuticals (IONS) over the last 13 years, with Q3 2025 value amounting to $31.1 million.

  • Ionis Pharmaceuticals' Share-based Compensation fell 262.01% to $31.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $126.7 million, marking a year-over-year increase of 524.47%. This contributed to the annual value of $130.2 million for FY2024, which is 2305.19% up from last year.
  • Ionis Pharmaceuticals' Share-based Compensation amounted to $31.1 million in Q3 2025, which was down 262.01% from $29.7 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' Share-based Compensation's 5-year high stood at $37.9 million during Q1 2021, with a 5-year trough of $22.3 million in Q4 2021.
  • In the last 5 years, Ionis Pharmaceuticals' Share-based Compensation had a median value of $29.7 million in 2025 and averaged $28.8 million.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Share-based Compensation crashed by 7657.93% in 2021 and then surged by 3725.7% in 2024.
  • Ionis Pharmaceuticals' Share-based Compensation (Quarter) stood at $22.3 million in 2021, then grew by 15.41% to $25.7 million in 2022, then increased by 2.52% to $26.3 million in 2023, then skyrocketed by 37.26% to $36.1 million in 2024, then fell by 13.84% to $31.1 million in 2025.
  • Its Share-based Compensation was $31.1 million in Q3 2025, compared to $29.7 million in Q2 2025 and $29.7 million in Q1 2025.